Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D04DYC
|
||||
Former ID |
DIB001112
|
||||
Drug Name |
PF-06463922
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Pfizer
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H20FN7O2
|
||||
InChI |
InChI=1S/C22H20FN7O2/c1-11-7-26-22-28-17-10-29(3)21(31)14-5-4-13(23)6-15(14)12(2)32-20-19(24)25-8-16(27-20)18(17)30(22)9-11/h4-9,12H,10H2,1-3H3,(H2,24,25)/t12-/m1/s1
|
||||
InChIKey |
WNAMTDCFIFUIGH-GFCCVEGCSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | ALK tyrosine kinase receptor | Target Info | Inhibitor | [533279] | |
KEGG Pathway | Non-small cell lung cancer | ||||
WikiPathways | Differentiation Pathway | ||||
References | |||||
Ref 524494 | ClinicalTrials.gov (NCT01970865) A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations. U.S. National Institutes of Health. | ||||
Ref 542499 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7476). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.